Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline
- 20 December 2019
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 26 (1), 151-155
- https://doi.org/10.1111/hae.13903
Abstract
Introduction The factor VIII mimetic emicizumab (Hemlibra, Hoffman‐la Roche, Basel, Switzerland) has a novel mode of action that affects the laboratory monitoring of patients receiving this treatment. Aim This guideline from the United Kingdom Haemophilia Centre Doctors Organisation (UKHCDO) aims to provide advice for clinical and laboratory staff on appropriate use of laboratory assays in patients with Haemophilia A treated with emicizumab. Methodology The guideline was prepared by a review of the available literature and discussion and revision by the authors. Results The guideline describes the effect of emicizumab on commonly used coagulations tests and provides recommendations on the use of assays for measurement of factor VIII and factor VIII inhibitor in the presence of emicizumab. The guideline also provides recommendations on measurement of emicizumab. Conclusion Knowledge of the effect of emicizumab on coagulation tests and factor assays is required to ensure appropriate testing and monitoring of therapy in patients receiving this drug.Keywords
This publication has 10 references indexed in Scilit:
- Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation AssaysThrombosis and Haemostasis, 2019
- Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 StudiesBlood, 2018
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without InhibitorsThe New England Journal of Medicine, 2018
- Laboratory testing for factor VIII and IX inhibitors in haemophilia: A reviewHaemophilia, 2018
- Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?Blood, 2017
- Emicizumab Prophylaxis in Hemophilia A with InhibitorsThe New England Journal of Medicine, 2017
- Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia AThe New England Journal of Medicine, 2016
- A first-in-human phase 1 study of ACE910, a novel factor VIII–mimetic bispecific antibody, in healthy subjectsBlood, 2016
- A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A modelNature Medicine, 2012
- Guidelines on the laboratory aspects of assays used in haemostasis and thrombosisInternational Journal of Laboratory Hematology, 2012